ContraFect Corp. | Ownership
Companies that own ContraFect Corp.
Baker Bros. Advisors LP
7,153,076
9.01%
0
0.1%
06/30/2018
Federated Global Investment Management Corp.
6,000,000
7.56%
0
0.09%
06/30/2018
Adage Capital Management LP
4,100,000
5.16%
0
0.02%
06/30/2018
Cormorant Asset Management LP
3,392,234
4.26%
0
0.53%
06/30/2018
BVF Partners LP
3,361,071
4.23%
-138,929
0.5%
06/30/2018
Oracle Investment Management, Inc.
3,224,733
4.05%
57,720
1.56%
06/30/2018
683 Capital Management LLC
2,324,836
2.93%
-175,164
0.57%
06/30/2018
The Vanguard Group, Inc.
2,108,202
2.66%
66,821
0%
06/30/2018
Birchview Capital LP
1,075,082
1.35%
-60,000
1.43%
06/30/2018
AXA Investment Managers UK Ltd.
562,517
0.71%
562,517
0.01%
06/30/2018
| Address |
28 Wells Avenue
Yonkers New York 10701
United States
|
|
Employees
|
- |
| Website |
http://www.contrafect.com |
| Updated |
07/08/2019 |
| ContraFect Corp. engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY. |
